The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target of the drug is relevant to pediatric oncology. This is expected to drive a substantial increase in the number of trials seeking to enroll children. Parents and caregivers are likely to have many questions when considering whether to enroll a child in a clinical trial, and children, perhaps particularly adolescents, will also have their own lists of questions, so adequate time must be allowed for these questions to be asked and answered.
Explore related content and topics
Blog
Challenges Arise as the Need for Pediatric Research Increases
Many modern providers prescribe off-label treatment to children with “guesstimated” doses, because these drugs have often only been studied in…
Blog
Mark Sorrentino: From Doctor, to Researcher, to Patient
Through his own participation in a medical trial, PRA's own Mark Sorrentino gained new perspective on what being a patient in a clinical trial is…
Blog
The RACE for Children Act: Early Global Impact and Ensuring Success with Pediatric Champions
Late last year, the CPCD hosted a webinar with Xtalks to update the industry on the impact the RACE Act legislation has had thus far. Read on for a…